The Global Multiple System Atrophy (MSA) Therapeutics Industry is poised for remarkable growth, with an estimated CAGR of 4.4%, reaching a valuation of US$ 137.3 Million in 2023. This upward trajectory is anticipated to elevate the market to a staggering US$ 211.1 Million by 2033, propelled by advancements in healthcare technology.
The surge in market share for multiple system atrophy is attributed to the escalating incidence of neurodegenerative illnesses. The impending launch of a groundbreaking medicine is anticipated to be a key driver for the growth of the multiple system atrophy market in the coming years, attracting new players entering the landscape due to the expiration of patent protection.
The landscape is witnessing a dynamic shift, with increasing government support and a rising awareness about neurodegenerative disorders contributing significantly to market growth. Furthermore, the augmentation of healthcare expenditure in developing countries and a simultaneous increase in patient awareness regarding the utilization of nerve monitoring devices are presenting novel opportunities for market players.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-16285
The manufacturers are involved in the production of multiple system atrophy therapeutics in a larger capacity. Research and innovation are also conducted to launch innovative products for multiple system atrophy therapeutics. For instance, Teva Pharmaceutical Industries Ltd. and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. Anle138b targets pathological alpha-synuclein oligomers and is being evaluated in patients with neurodegenerative diseases for potential disease modification.
North America dominates the multiple system atrophy therapeutics market due to the presence of key market players’ presence, along with recent product launches and established healthcare infrastructure, which will accelerate the market’s growth in the region. The significant R&D investments in Europe abode well for market growth.
Key Takeaways from the Global Multiple System Atrophy (MSA) Therapeutics Industry Study
- As of 2023, the multiple system atrophy therapeutics market was valued at US$137.3 Million
- From 2023 to 2033, the multiple system atrophy therapeutics industry is poised to grow at an 4.4% CAGR
- By 2033, the multiple system atrophy therapeutics market is slated to reach a valuation of US$211.1 Million
- Based on diagnosis, PET scan segment dominated the market in 2023 with a revenue share of 34.6%.
- China is poised to yield a CAGR of 4.1% to multiple system atrophy therapeutics through 2033
“Growing healthcare spending and increase in the prevalence of neurological disorders are expected to radically transform the multiple system atrophy therapeutics market in the coming years,” comments an analyst at FMI.
Competitive Landscape
are some of the key players in the chronic smell and flavour loss treatment market like Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, Theravance Biopharma, Inc., Merck & Co., Neuropore Therapies Inc, Newron Pharmaceuticals SpA, ProMIS Neurosciences Inc, Stealth BioTherapeutics Corp, Chelsea Therapeutics International, Ltd. and others.
The manufacturers are involved in the production of multiple system atrophy(MSA) therapeutics larger capacity. Research and innovation are also conducted to launch innovative products for multiple system atrophy(MSA) therapeutics.
In April 2022, ProMIS Neurosciences, Inc. a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteinssuch as toxic oligomers implicated in the development of neurodegenerative diseases, announced today new milestones in potential therapeutic approaches for ALS.
In October 2022, Biohaven Ltd. announced advancements in the development of its MoDE extracellular target degrader platform technology licensed from Yale University for various disease indications, including, but not limited to, neurological disorders, cancer, infectious and autoimmune diseases.
Click Here to Request Methodology! https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16285
Key Segments Covered in the Global Multiple System Atrophy (MSA) Therapeutics Industry Survey
Global Multiple System Atrophy (MSA) Therapeutics Industry by Type:
- Parkinsonian
- Cerebellar
Global Multiple System Atrophy (MSA) Therapeutics Industry by Diagnosis:
- Magnetic Resonance Imaging (MRI)
- Positron Emission Tomography (PET)
- Single Photon Emission Computed Tomography (SPECT)
- Tilt Table Test
- Others
Global Multiple System Atrophy (MSA) Therapeutics Industry by Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- MEA
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Nandini Singh Sawlani
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
